截至2026年1月21日 13:11，中证医药及医疗器械创新指数(931484)上涨0.03%，成分股特宝生物上涨 3.38%，甘李药业上涨2.24%，英科医疗上涨1.70%，康龙化成上涨1.23%，大博医疗上涨1.16%。医疗创 新ETF(516820)多空胶着，最新报价0.37元。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由 ...

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index rising by 0.55% and several constituent stocks showing significant gains [1] - The Medical Innovation ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 6.0262 million and a total of 11.2443 million, averaging 3.7481 million per day [1] - The National Healthcare Security Administration issued a guideline aimed at standardizing pricing for surgical and treatment auxiliary services, promoting a shift from traditional treatment to precision medicine [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, accounting for 63.75% of the total index weight [2]

Summary of Semiconductor Equipment Industry Conference Call Industry Overview - The semiconductor equipment industry is experiencing a supply-demand imbalance, particularly in storage solutions, driven by the surge in artificial intelligence (AI) demand. This situation is expected to persist for some time, affecting both enterprise and consumer-grade solid-state drives (SSDs) [1][2]. Key Companies and Insights Kioxia - Kioxia's storage division manager, Jun Saito, indicated that the supply-demand tightness will continue, leading to shortages in both enterprise and consumer SSDs [1][2]. Jinhai Tong - Focuses on the translation sorting machine, benefiting from the launch of the 9000 series three-temperature sorting machine, which has significantly increased automotive electronics revenue. The company is also developing high-end sorting machines for AI chips, anticipating substantial order breakthroughs in 2026 with projected revenues of 14 billion and profits of 5 billion [3]. Huafeng Measurement and Control - The 8600 GPU testing machine is leading in testing channel count, frequency, and parallel processing capabilities domestically. Small-scale production validation has been completed, with a high likelihood of securing large orders in 2026 [3]. Jingce Electronics - The company has seen significant order growth, especially in Hefei, with expectations for continued growth in 2026. It leads in fields such as film thickness, OCD, and electron beam technologies, with advancements in 14nm technology expected this year [3]. Qiangyi Co., Ltd. - The company has engaged with major clients in the computing chip sector and has completed deliveries or initial validations of 2.5D MEMS probe cards for HBM, NOR Flash, and DRAM. With overseas probe card shortages, the company is expected to exceed performance expectations in 2026 [3]. Changchuan Technology - Deeply integrated with H, the storage testing machine is set for a breakout year, with expected revenues of 15 billion. The GPU testing machine holds a significant market share in H's computing chip testing, with strong order backlogs [4]. Jingzhida - A leader in high-speed FT testing machines, the company is actively validating its products with clients, expecting to double orders and revenue this year, driven by two storage products [4]. Weida Nano - Primarily serving two storage clients, the company has seen a doubling of new orders in 2025, with mature products gaining traction among new clients and expectations for order upgrades in 2026 [4]. Maiwei Co., Ltd. - Focused on etching and ALD in the semiconductor sector, the company anticipates approximately 8 billion in front-end equipment orders for 2025, with two-thirds attributed to storage. The target for front-end orders in 2026 is set at 20 billion, with an optimistic outlook for continued growth [4]. Additional Insights - The semiconductor equipment sector is poised for growth due to increased capital expenditures in domestic and international fabs, indicating a robust investment environment [1][2]. - The ongoing demand for AI and related technologies is expected to drive further advancements and opportunities within the industry [1][2].

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Group 1 - The core point of the article is that TeBao Bio announced the renewal of the "Joint Action Agreement" between its actual controllers, Yang Ying and Sun Li, to ensure the company's stable development and operational continuity [2][3] - The renewal of the agreement was prompted by the impending expiration of the previous agreement signed on January 16, 2023 [2] - The company aims to promote steady growth and safeguard operational stability through this renewed agreement [2]

厦门特宝生物工程股份有限公司 关于实际控制人续签一致行动协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于 2025 年 1 月 16 日收 到公司实际控制人杨英女士和孙黎先生续签《一致行动协议》的通知。鉴于双方于 2023 年 1 月 16 日签署的《一致行动协议》（以下简称"原协议"）有效期即将届 满，为促进公司稳健发展，保障经营的连续性和稳定性，双方续签了《一致行动协 议》，具体情况如下： 一、本次续签《一致行动协议》的背景情况 杨英女士和孙黎先生于 2023 年 1 月 16 日签署了原协议，双方约定在协议有效 期内对公司重要事项的决策保持一致行动，并做出相同的意思表示和行为。原协议 自 2023 年 1 月 17 日起生效，有效期三年。原协议签署至今，杨英女士和孙黎先生 均充分遵守有关一致行动的约定和承诺，未发生违反原协议的情形。 证券代码：688278 证券简称：特宝生物 公告编号：2026-001 鉴于原协议有效期即将届满，为促进公司稳健发展，保障经 ...

Core Insights - The biopharmaceutical industry in China is a strategic emerging industry, crucial for public health, technological innovation, and enhancing national pharmaceutical autonomy. The market size is projected to grow from CNY 4,210 billion in 2022 to CNY 8,000 billion by 2028, with an annual growth rate stabilizing between 10%-12% [1][2][23]. Industry Overview - In 2020, the biopharmaceutical market in China was valued at CNY 3,457 billion, increasing to CNY 4,100 billion in 2021, representing an 18.6% year-on-year growth. However, growth slowed to 2.68% in 2022, with a slight increase to CNY 4,210 billion [1][2]. - The industry is segmented into upstream (raw materials and medical devices), midstream (drug synthesis and production), and downstream (drug distribution). Biopharmaceuticals and chemical drugs have higher profit margins, with biopharmaceutical companies reporting gross margins of 80%-86% [2][4]. Xiamen Biopharmaceutical Industry - Xiamen is a key hub for biopharmaceutical industry development, recognized as a national strategic emerging industry cluster. The local government has implemented various supportive policies since 2016, focusing on innovation and industrialization [6][9]. - The industrial output value of Xiamen's biopharmaceutical sector reached CNY 1,045.87 billion in 2022, with a slight decline to CNY 847 billion in 2023, and is projected to stabilize around CNY 840 billion in 2024 [17][18]. Policy Environment - Xiamen's government has introduced multiple measures to support the biopharmaceutical industry, including financial incentives for R&D and commercialization, with significant rewards for new drug development and medical device innovation [9][26]. - The city aims to establish a CNY 100 billion venture capital fund and enhance the entire process from R&D to clinical application by 2025 [23][26]. Future Outlook - By 2025, Xiamen plans to significantly increase the number of registered biopharmaceutical companies, with projections indicating over 2,200 registered firms, marking a notable rise from previous years [18]. - The city aims to develop a CNY 700 billion biopharmaceutical industry chain, supported by specialized parks and a focus on various sub-sectors, including biopharmaceuticals and medical devices [23][26].

Core Viewpoint - The stock of TEBIO has experienced a decline of 8.58% since the beginning of the year, with significant trading activity noted on January 15, 2025, where the stock price reached 76.50 CNY per share, reflecting a market capitalization of 31.23 billion CNY [1] Group 1: Stock Performance - On January 15, 2025, TEBIO's stock rose by 2.08%, with a trading volume of 1.11 billion CNY and a turnover rate of 0.36% [1] - The stock has seen a decline of 6.79% over the last five trading days, 8.16% over the last twenty days, and 2.61% over the last sixty days [1] Group 2: Financial Performance - For the period from January to September 2025, TEBIO reported a revenue of 2.48 billion CNY, representing a year-on-year growth of 26.85%, and a net profit attributable to shareholders of 666 million CNY, which is a 20.21% increase year-on-year [2] - Since its A-share listing, TEBIO has distributed a total of 577 million CNY in dividends, with 506 million CNY distributed over the past three years [2] Group 3: Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2.00% from the previous period, with an average of 47,258 circulating shares per shareholder, a decrease of 1.96% [2] - The top ten circulating shareholders include notable ETFs, with E Fund's SSE STAR 50 ETF holding 5.88 million shares, down by 856,700 shares from the previous period, and Huaxia's SSE STAR 50 Component ETF holding 5.73 million shares, down by 3.22 million shares [2]

Group 1: Earnings Forecasts - Over 40 A-share companies disclosed their earnings forecasts or reports for 2025 on January 14, including popular stocks like Jiamei Packaging and Haige Communication [1] - Jinhaitong is expected to achieve a net profit of 160 million to 210 million yuan in 2025, representing a year-on-year increase of 103.87% to 167.58% [1] - Yonghe Co. anticipates a net profit of 530 million to 630 million yuan, with a year-on-year growth of 110.87% to 150.66% [2] Group 2: Industry Trends - The refrigerant industry is expected to maintain a high level of prosperity in 2025, with smooth production and sales connections, leading to increased revenue and gross margin [2] - The semiconductor packaging and testing equipment sector is experiencing sustained demand growth, contributing to Jinhaitong's performance [1] Group 3: Performance Declines - Jiamei Packaging forecasts a net profit of 85.437 million to 104 million yuan for 2025, a decline of 43.02% to 53.38% year-on-year, attributed to a "small year" in the beverage industry [3] - Haige Communication expects to report a net loss for 2025 due to industry client adjustments and increased investment in innovative businesses [6]